2 more firms seek FDA nod on COVID-19 vaccines | Inquirer News

2 more firms seek FDA nod on COVID-19 vaccines

/ 05:14 AM July 22, 2023

Two new applications—one for monovalent and the other for bivalent vaccines—are pending with the Food and Drug Administration (FDA) for their commercial use against COVID-19, according to Director General Samuel Zacate.

The FDA chief, however, did not elaborate. So far, only Pfizer’s bivalent vaccine under the brand name Comirnaty Original/Omicron BA.4-5 was given the certificate of product registration, a license issued by the FDA for the commercial distribution and sale of a medical device.

ADVERTISEMENT

The FDA is hoping Pfizer can finally bring in commercial batches of bivalent vaccine Tozinameran Famtozinameran by the end of this month or in August, Zacate said.

The jabs may be sold to consumers 12 years old and above and administered by a medical professional as a booster shot. —Kathleen de Villa

FEATURED STORIES

RELATED STORY:

Bivalent COVID-19 jabs need prescription – FDA 

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Coronavirus, COVID-19, FDA, Health, vaccine
For feedback, complaints, or inquiries, contact us.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

News that matters

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.



© Copyright 1997-2023 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.